000100.KS
Yuhan Corporation
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 81,400.00
+0.12%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2282.3B | 2186.6B | 2067.8B | 1859.0B | 1775.8B |
| Cost of Revenue | 1499.4B | 1458.2B | 1378.4B | 1294.5B | 1257.6B |
| Gross Profit | 782.9B | 728.5B | 689.4B | 564.5B | 518.2B |
| Operating Expenses | |||||
| R&D Expense | 181.4B | 227.3B | 224.8B | 119.9B | 107.1B |
| SG&A Expense | 140.8B | 191.2B | 207.7B | 370.0B | 200.4B |
| General & Admin Expense | 24.7B | 32.7B | 32.2B | 31.1B | 27.7B |
| Selling & Marketing Expense | 116.0B | 158.5B | 175.5B | 175.7B | 172.7B |
| Other Expenses | 414.0B | 204.6B | 202.1B | 182.1B | 174.7B |
| Total Operating Expenses | 658.1B | 623.2B | 634.5B | 489.9B | 482.2B |
| Cost and Expenses | 2158.5B | 2082.3B | 2012.9B | 1784.4B | 1739.8B |
| Operating Income (EBIT) | 124.7B | 123.6B | 54.9B | 74.6B | 36.0B |
| Non-Operating | |||||
| Interest Income | 9.0B | 8.2B | 8.6B | 11.2B | 9.6B |
| Interest Expense | 15.6B | 15.4B | 14.7B | 2.5B | 3.5B |
| Net Interest Income | (6.7B) | (7.2B) | (6.1B) | 8.7B | 6.1B |
| Other Non-Op Income/Expense | 149.3B | 118.3B | 6.6B | 77.8B | 58.9B |
| Non-Operating Income (excl Interest) | (115.9B) | 18.2B | (21.3B) | (8.2B) | 977.6M |
| EBT (Pre-Tax Income) | 273.2B | 222.7B | 61.4B | 134.8B | 94.9B |
| Income Tax Expense | 50.5B | 37.4B | 6.3B | 571.4M | 4.3B |
| Bottom Line | |||||
| Net Income | 237.1B | 194.1B | 70.7B | 136.2B | 95.1B |
| Earnings from Cont. Ops | 222.7B | 185.3B | 55.2B | 134.2B | 90.6B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 234.8B | 194.1B | 70.7B | 136.2B | 95.1B |
| Per Share | |||||
| Basic EPS | ₩2,715 | ₩2,599 | ₩943 | ₩1,816 | ₩1,207 |
| Diluted EPS | ₩2,715 | ₩2,599 | ₩943 | ₩1,816 | ₩1,207 |
| Revenue Per Share | ₩26,711 | ₩26,946 | ₩27,585 | ₩24,787 | ₩23,620 |
| Shares | |||||
| Basic Shares Outstanding | 85.4M | 81.1M | 75.0M | 75.0M | 75.2M |
| Diluted Shares Outstanding | 85.4M | 81.1M | 75.0M | 75.0M | 75.2M |
| Profitability Metrics | |||||
| EBITDA | 219.7B | 174.5B | 139.2B | 127.4B | 78.1B |
| D&A | 77.7B | 69.2B | 63.0B | 44.7B | 43.0B |
| EBIT | 141.9B | 105.3B | 76.2B | 82.8B | 35.1B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026